TheStreet upgraded shares of Pacira Pharmaceuticals (NASDAQ:PCRX) from a d+ rating to a c rating in a research note published on Friday morning.

A number of other research analysts have also weighed in on PCRX. Wedbush restated an outperform rating and set a $80.00 price objective on shares of Pacira Pharmaceuticals in a research report on Monday, April 30th. HC Wainwright set a $48.00 price objective on Pacira Pharmaceuticals and gave the company a buy rating in a research report on Thursday, May 3rd. Mizuho restated a hold rating and set a $31.00 price objective on shares of Pacira Pharmaceuticals in a research report on Thursday, May 3rd. Canaccord Genuity set a $34.00 price objective on Pacira Pharmaceuticals and gave the company a hold rating in a research report on Thursday, May 3rd. Finally, JMP Securities set a $56.00 price target on Pacira Pharmaceuticals and gave the stock a buy rating in a research report on Friday, May 4th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and ten have assigned a buy rating to the company’s stock. Pacira Pharmaceuticals currently has a consensus rating of Hold and a consensus target price of $46.56.

Shares of Pacira Pharmaceuticals stock opened at $46.95 on Friday. The stock has a market cap of $1.88 billion, a PE ratio of -80.95 and a beta of 1.83. The company has a quick ratio of 7.79, a current ratio of 8.58 and a debt-to-equity ratio of 0.98. Pacira Pharmaceuticals has a twelve month low of $26.95 and a twelve month high of $47.55.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings data on Thursday, August 2nd. The company reported $0.24 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.37. The firm had revenue of $84.10 million during the quarter, compared to analyst estimates of $77.53 million. Pacira Pharmaceuticals had a negative return on equity of 0.39% and a negative net margin of 3.64%. The business’s quarterly revenue was up 18.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.11) earnings per share. analysts anticipate that Pacira Pharmaceuticals will post -0.51 earnings per share for the current fiscal year.

In other Pacira Pharmaceuticals news, VP Lauren Bullaro Riker sold 801 shares of the business’s stock in a transaction that occurred on Monday, June 4th. The stock was sold at an average price of $33.02, for a total transaction of $26,449.02. Following the completion of the transaction, the vice president now owns 9,641 shares in the company, valued at $318,345.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO David M. Stack sold 18,406 shares of the business’s stock in a transaction that occurred on Thursday, June 7th. The shares were sold at an average price of $36.28, for a total value of $667,769.68. Following the transaction, the chief executive officer now owns 91,831 shares of the company’s stock, valued at approximately $3,331,628.68. The disclosure for this sale can be found here. In the last quarter, insiders sold 24,093 shares of company stock valued at $856,233. 5.90% of the stock is currently owned by company insiders.

Several large investors have recently made changes to their positions in PCRX. venBio Select Advisor LLC boosted its position in shares of Pacira Pharmaceuticals by 102.1% during the first quarter. venBio Select Advisor LLC now owns 1,715,072 shares of the company’s stock valued at $53,424,000 after buying an additional 866,500 shares during the period. PointState Capital LP boosted its position in shares of Pacira Pharmaceuticals by 71.1% during the first quarter. PointState Capital LP now owns 2,038,153 shares of the company’s stock valued at $63,488,000 after buying an additional 847,146 shares during the period. Nexthera Capital LP purchased a new position in shares of Pacira Pharmaceuticals during the first quarter valued at approximately $14,909,000. Summit Trail Advisors LLC boosted its position in shares of Pacira Pharmaceuticals by 2,888.3% during the first quarter. Summit Trail Advisors LLC now owns 399,688 shares of the company’s stock valued at $400,000 after buying an additional 386,313 shares during the period. Finally, Millennium Management LLC boosted its position in shares of Pacira Pharmaceuticals by 64.6% during the first quarter. Millennium Management LLC now owns 888,391 shares of the company’s stock valued at $27,673,000 after buying an additional 348,542 shares during the period.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Further Reading: Outstanding Shares, Buying and Selling Stocks

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.